Literature DB >> 24844919

Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer.

Maja Lynge Rasmussen1, Gabor Liposits, Subethini Yogendram, Anders Bonde Jensen, Søren Linnet, Sven Tyge Langkjer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24844919     DOI： 10.3109/0284186X.2014.918277

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  2 in total

1.  Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer.

Authors:  Pei-Hsin Chen; Dah-Cherng Yeh; Heng-Hsin Tung; Chin-Yao Lin
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

2.  Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.

Authors:  Mélodie Dell'Ova; Eléonora De Maio; Séverine Guiu; Lise Roca; Florence Dalenc; Anna Durigova; Frédéric Pinguet; Khedidja Bekhtari; William Jacot; Stéphane Pouderoux
Journal:  BMC Cancer       Date:  2015-10-08       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.